Adel Nada, GentiBio CEO
In bid for new T cell therapies, Bristol Myers inks deal with Treg player GentiBio
A myriad of rare T cell types has popped on the radar in recent years as companies search for the next generation of T cell …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
